Overall Score

Capital Allocation

Balance sheet remains conservative with a current ratio of 4.35 and low debt-to-equity of 0.06.

However, profitability and cash generation remain weak, with return on equity at -40.5% and free cash flow per share at -0.66.

Management is still prioritizing R&D-heavy investment, with research and development at 83.2% of revenue.

Execution

Gross profit margin remains very strong at 116.3%, indicating the core economics of the product remain favorable.

Operating performance is still deeply negative, with operating margin at -92.7% and operating cash flow margin at -81.3%.

Working capital remains positive at $357.4M, but the cash conversion cycle is still unfavorable at -87.7 days.

Governance

No material governance red flags are evident from the available financial data.

Stock-based compensation remains meaningful at 14.4% of revenue, which continues to dilute shareholders.

The company’s low leverage and strong liquidity reduce near-term financial stress risk.